SLC2A1 and glycogen storage disease V: Beyond LC-FAODs, medium-chain acylcarnitines may provide therapeutic value in a range of other metabolic disorders that have failed to respond to triheptanoin, such as McArdle’s disease, phosphofructokinase deficiency, GLUT1 deficiency, pyruvate carboxylase deficiency, and alternating hemiplegia of childhood (48–52).